Recombinant Human Growth Hormone not checked
Changchun GeneScience Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
3 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.”In the company’s words, NCT07016802 on ClinicalTrials.gov
- Tested for
- Short Bowel Syndrome (SBS) in Adults, Pediatric Growth Hormone Deficiency, Safety, Tolerability, Adult Growth Hormone Deficiency
- Main trialPhase 4
- “This is a multicenter, open-label, single-arm clinical trial. A total of 100 participants with short bowel syndrome (SBS) receiving parenteral nutrition (PN) support are planned to be enrolled. The trial includes a 2-week run-in phase and a 4-week intervention phase, during which participants will receive rhGH injections. A safety follow-up period will then be conducted through Week 52.”In the company’s words, NCT07691125 on ClinicalTrials.gov
- Other names
- rhGH
Other drugs for Short Bowel Syndrome (SBS) in Adults
- TeduglutideTakeda · Phase 3
- ApraglutideVectivBio AG · Phase 3
- GlepaglutideZealand Pharma · Phase 3
- PJ009Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 3
- CrofelemerNapo Pharmaceuticals, Inc. · Phase 2
- FT1Chongqing Peg-Bio Biopharm Co., Ltd. · Phase 2
Coming up3
- 25 NovPhase 1 trial completes · ClinicalTrials.gov
- 28 Apr 2027Phase 4 trial completes · ClinicalTrials.gov
- Nov 2030Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Recruiting | 28 Apr 2027 | Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome | |
| Phase 1/2Recruiting | Nov 2030 | A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD) | |
| Phase 1Recruiting | 25 Nov 2026 | A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD) | |
| Phase 4Completed | 25 Aug 2025 | A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026